Endothelin 1 in cancer: Biological implications and therapeutic opportunities

Nature Reviews Cancer

Volumn 13, Issue 9, 2013, Pages 637-651

  Rosanò, Laura ^a   Spinella, Francesca ^a   Bagnato, Anna ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; BETA ARRESTIN 1; BETA CATENIN; BIOLOGICAL MARKER; BOSENTAN; CONNEXIN 43; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOOXYGENASE 1; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; GELATINASE A; HISTONE H3; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; MACITENTAN; NEBENTAN; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; SURVIVIN; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR 3; VITRONECTIN RECEPTOR; ZIBOTENTAN;

ANGIOGENESIS; APOPTOSIS; BINDING SITE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; DENDRITIC CELL; DNA BINDING; EPITHELIAL MESENCHYMAL TRANSITION; HISTONE ACETYLATION; HUMAN; IMMUNOCOMPETENT CELL; INTRACELLULAR SIGNALING; LYMPHOCYTE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PARACRINE SIGNALING; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; THERAPY RESISTANCE; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

AUTOCRINE COMMUNICATION; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIN-1; HUMANS; LYMPHANGIOGENESIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PARACRINE COMMUNICATION; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84883153220     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3546     Document Type: Review

References (149)

1. Nelson, J., Bagnato, A., Battistini, B. & Nisen, P. The endothelin axis: emerging role in cancer. Nature Rev. Cancer 3, 110-116 (2003).
2. Nelson, J. B. et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med. 1, 944-949 (1995).
3. Bagnato, A. et al. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin. Cancer Res. 1, 1059-1066 (1995).
4. Yanagisawa, M. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415 (1988).
5. Ling, L., Maguire, J. J. & Davenport, A. P. Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer. Br. J. Pharmacol. 168, 283-295 (2013).
6. Stow, L. R., Jacobs, M. E., Wingo, C. S., Cain, B. D. Endothelin-1 gene regulation. FASEB J. 25, 16-28 (2011).
7. Matteucci, E. et al. Epigenetic control of endothelin-1 axis affects invasiveness of breast carcinoma cells with bone tropism. Exp. Cell Res. 319, 1865-1874(2013).
8. Li, D. et al. The inhibitory effect of miRNA-1 on ET-1 gene expression. FEBS Lett. 586, 1014-1021 (2012).
9. Li, D. et al. MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sci. 91, 440-447 (2012).
10. Moraitis, S., Miller, W. R., Smyth, J. F. & Langdon, S. P. Paracrine regulation of ovarian cancer by endothelin. Eur. J. Cancer 35, 1381-1387 (1999).
11. Shukla, A. K., Xiao, K. & Lefkowitz, R. J. Emerging paradigms of arrestin-dependent seven transmembrane receptor signaling. Trends Biochem. Sci. 36, 457-469 (2011).
12. Maguire, J. J. et al. Comparison of human ETA and ETB receptor signalling via G-protein and arrestin pathways. Life Sci. 91, 544-549 (2012).
13. Daub, H., Weiss, F. U., Wallasch, C. & Ullrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557-560 (1996).
14. Vacca, F., Bagnato, A., Catt, K. J. & Tecce, R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signalling in human ovarian carcinoma cells. Cancer Res. 60, 5310-5317 (2000).
15. Rosan-, L. et al. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res. 67, 6351-6359 (2007).
16. Rosan ó, L. et al. ß-arrestin links endothelin A receptor to ß-catenin signalling to induce ovarian cancer cell invasion and metastasis. Proc. Natl Acad. Sci. USA 106, 2806-2811 (2009).
17. Spinella, F. et al. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. J. Mol. Med 91, 395-405 (2013).
18. Hinsley, E. E., Hunt, S., Hunter, K. D., Whawell, S. A. & Lambert, D. W. Endothelin-1 stimulates motility of head and neck squamous carcinoma cells by promoting stromal-epithelial interactions. Int. J. Cancer 130, 40-47 (2012).
19. Kim, T. H., Xiong, H., Zhang, Z. & Ren, B. ß-catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene 24, 597-604 (2005).
20. Sun, P., Xiong, H., Kim, T. H., Ren, B. & Zhang, Z. Positive inter-regulation between ß-catenin/T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells. Mol. Pharmacol. 69, 520-531 (2006).
21. Rosanó, L. et al. ß-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced ß-catenin signaling. Oncogene http://dx.doi. org/10.1038/onc.2012.527(2012).
22. Bagnato, A. et al. Growth inhibition of cervix carcinoma cell in vivo by endothelin A receptor blockade. Cancer Res. 62, 6381-6384 (2002).
23. Rosanó, L. et al. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol. Cancer Ther. 6, 2003-2011 (2007).
24. Rosanó, L. et al. Therapeutic targeting of the endothelin A receptor in human ovarian carcinoma. Cancer Res. 63, 2447-2453 (2003).
25. Banerjee, S. et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 67, 3818-3826 (2007).
26. Del Bufalo, D. et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol. Pharmacol. 61, 524-532 (2002).
27. Nelson, J. B., Udan, M. S., Guruli, G. & Pflug, B. R. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 7, 631-637 (2005).
28. Eberl, L. P., Valdenaire, O., Saintgiorgio, V., Jeannin, J. F. & Juillerat-Jeanneret, L. Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int. J. Cancer 86, 182-187 (2000).
29. Akhavan, A. et al. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 8, 725-732 (2006).
30. Kim, S. J. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. Neoplasia 13, 167-179 (2011).
31. Kim, S. J. et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl. Oncol. 5, 39-47 (2012).
32. Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Rev. Cancer 9, 265-273 (2009).
33. Ha, N. et al. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res. 71, 7259-7269 (2011).
34. Rosanó, L. et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 61, 8340-8346 (2001).
35. Wu, M. H. et al. Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways. J. Cell. Phisiol. 227, 3016-3026 (2012).
36. Bagnato, A., Tecce, R., Di Castro, V. & Catt, K. J. Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res. 57, 1306-1311 (1997).
37. Lange, K. et al. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res. 67, 6163-6173 (2007).
38. Rosanó, L. et al. Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol. Cancer Ther. 5, 833-842 (2006).
39. Bagnato, A. et al. Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res. 64, 1436-1443 (2004).
40. Spinella, F. et al. Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J. Biol. Chem. 278, 41294-41301 (2003).
41. Rosanó, L. et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res. 65, 11649-11657 (2005).
42. Peng, J. et al. ROCK cooperated with ET-1 to induce epithelial to mesenchymal transition through SLUG in human ovarian cancer cells. Biosci. Biotechnol. Biochem.76, 42-47 (2012).
43. Jamal, S. & Schneider, R. J. UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells. J. Clin. Invest. 110, 443-452 (2002).
44. Spinella, F. et al. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1 in human melanoma cells. Cancer Res. 67, 1725-1734 (2007).
45. Spinella, F., Rosanó, L., Di Castro, V., Natali, P. G. & Bagnato, A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducibile factor-1 in ovarian carcinoma cells. J. Biol. Chem. 277, 27850-27855 (2002).
46. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
47. Coffman, L. et al. Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer Biol. Ther. 14, 184-192 (2013).
48. Liu, Q. et al. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J. Neurooncol. 94, 1-19 (2009).
49. Liu, Y. et al. Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells. Mol. Cancer Res. 9, 1668-1685 (2011).
50. Puglisi, M. A. et al. Identification of Endothelin-1 and NR4A2 as CD133-regulated genes in colon cancer cells. J. Pathol. 225, 305-314 (2011).
51. Wiesmann, F. Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer. Breast Cancer Res. 11, R34 (2009).
52. Sun, de J. et al. Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells. Hum. Pathol. 38, 1047-1056 (2007).
53. Jazaeri, A. A. et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin. Cancer Res. 11, 6300-6310 (2005).
54. Helleman, J., Smid, M., Jansen, M. P., van der Burg, M. E. & Beins, E. M. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol. Oncol. 117, 170-176 (2010).
55. Rosanó, L. et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin. Cancer Res. 17, 2350-2360 (2011).
56. Ghoul, A. et al. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res. 69, 4260-4269 (2009).
57. Cruz-Muz, W. et al. Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Res. 72, 4909-4919 (2012).
58. Titus, B. et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res. 65, 7320-7327 (2005).
59. Said, N., Smith, S., Sanchez-Carbayo, M. & Theodorescu, D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J. Clin. Invest. 121, 132-147 (2011).
60. Yin, J. J. et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastasis. Proc. Natl Acad. Sci. USA 100, 10954-10959 (2003).
61. Guise, T. A. et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res.12, 6213-6216 (2006).
62. Clines, G. A. et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol. Endocrinol. 21, 486-498 (2007).
63. Dru, D. et al. Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis. Clin. Exp. Metastasis 23, 41-53 (2006).
64. Khodorova, A. et al. Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nature Med. 9, 1055-1061 (2003).
65. Yuyama, H. et al. Effects of selective endothelin ETA receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur. J. Pharmacol. 492, 177-182 (2004).
66. Quang, P. N. & Schmidt, B. L. Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice. Pain 149, 254-262 (2010).
67. Spinella, F. et al. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res. 69, 2669-2676 (2009).
68. Salani, D. et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. 157, 1703-1711 (2000).
69. Wu, M. H. et al. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells. Oncogene http://dx.doi. org/10.1038/onc.2013.109 (2013).
70. Salani, D. et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am. J. Pathol. 157, 1537-1547 (2000).
71. Wfing, P. et al. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin. Cancer Res. 9, 4125-4131 (2003).
72. Wfing, P. et al. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br. J. Cancer 92, 1720-1728 (2005).
73. Clasper, S. et al. A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res. 68, 7293-7303 (2008).
74. Cueni, L. N. et al. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am. J. Pathol. 177, 1004-1016 (2010).
75. Spinella, F. et al. Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1 in melanoma cells. PLoS ONE 5, e11241 (2010).
76. Wilson, J. L., Burchell, J. & Grimshaw, M. J. Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res. 66, 11802-11807 (2006).
77. Grimshaw, M. J. Endothelins and hypoxia-inducible factor in cancer. Endocr. Relat. Cancer 14, 233-244 (2007).
78. Spinella, F. et al. Inhibition of cyclooxygenase-1 and-2 expression by targeting the endothelin A receptor in human ovarian carcinoma cells. Clin. Cancer Res. 10, 4670-4679 (2004).
79. Huang, W. H. et al. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene http://dx.doi.org/10.1038/onc.2012.458 (2012).
80. Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540 (2000).
81. Knowles, J. P. et al. Endothelin-1 stimulates colon cancer adjacent fibroblasts. Int. J. Cancer 130, 1264-1272 (2012).
82. Haque, S. U. et al. Efficacy of the specific endothelin A receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study. Mol Cancer Ther. 30 May 2013 (http://dx.doi.org/10.1158/1535-7163. MCT-12-0975).
83. Schrey, M. P., Patel, K. V. & Tezapsidis, N. Bombesin and glucocorticoids stimulate human breast cancer cells to produce endothelin, a paracrine mitogen for breast stromal cells. Cancer Res. 52, 1786-1790 (1992).
84. Patel, K. V., Sheth, H. G. & Schrey, M. P. Stimulation or endothelin-1 secretion by human breast cancer cells through protein kinase A activation: a possible novel paracrine loop involving breast fibroblast-derived prostaglandin E2. Mol. Cell. Endocrinol. 126, 143-151 (1997).
85. Guruli, G. et al. Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood 104, 2107-2115 (2004).
86. Kandalaft, L. E., Motz, G. T., Duraiswamy, J. & Coukos, G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev. 30, 141-151 (2011).
87. Kandalaft, L. E., Facciabene, A., Buckanovich, R. J. & Coukos, G. Endothelin B receptor, a new target in cancer immune therapy. Clin. Cancer Res. 15, 4521-4528 (2009).
88. Buckanovich, R. J. et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nature Med. 14, 28-36 (2008).
89. Rosanó, L. et al. Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am. J. Pathol. 163, 753-762 (2003).
90. Lahav, R., Heffner, G. & Patterson, P. H. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc. Natl Acad. Sci. USA 96, 11496-11500 (1999).
91. Venuti, A., Salani, D., Manni, V., Poggiali, F. & Bagnato, A. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J. 14, 2277-2283 (2000).
92. Egidy, G. et al. Modulation of human colon tumor-stromal interactions by the endothelin system. Am. J. Pathol.157, 1863-1874 (2000).
93. Li, Y. et al. Knockdown of endothelin A receptor expression inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model. Mol. Med. Rep. 5, 1391-1395 (2012).
94. Groenewegen, G. et al. Targeting the endothelin axis with atrasentan, in combination with IFN-, in metastatic renal cell carcinoma. Br. J. Cancer 106, 284-289 (2012).
95. Bher, K. et al. Assessment of endothelin-A receptor expression in subcutaneous and orthotopic thyroid carcinoma xenografts in vivo employing optical imaging methods. Endocrinology 153, 2907-2918 (2012).
96. Ishimoto, S. et al. Role of endothelin receptor signalling in squamous cell carcinoma. Int. J. Oncol. 40, 1011-1019 (2012).
97. Pagotto, U. et al. Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoral growth. J. Clin. Invest. 96, 2017-2025 (1995).
98. Bagnato, A. et al. Role of the endothelin axis and its antagonists in the treatment of cancer. Br. J. Pharmacol. 163, 220-233 (2011).
99. Rajeshkumar, N. V., Rai, A. & Gulati, A. Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Res. Treat. 94, 237-247 (2005).
100. Gulati, A., Sunila, E. S. & Kuttan, G. IRL-1620, an endothelin-B receptor agonist, enhanced radiation induced reduction in tumor volume in Dalton's Lymphoma Ascites tumor model. Arzneimittelforschung 62, 14-17 (2012).
101. Spinella, F. et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signalling pathways in ovarian carcinoma. Mol. Cancer Ther. 5, 1483-1492 (2006).
102. Corder, R. et al. Endothelin-1 synthesis reduced by red wine. Nature 414, 863-864 (2001).
103. Papandreou, C. N. et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Med. 4, 50-57 (1998).
104. Kajiyama, H. et al. Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo. Clin. Cancer Res. 11, 1798-1808 (2005).
105. Morris, C. D. et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br. J. Cancer 92, 2148-2152 (2005).
106. Miller, K. et al. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 16,187-192 (2013).
107. Yu, E. Y. et al. Detection of previously unidentified metastatic disease as a leading cause of screening failure in a Phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. J. Urol.188, 103-109 (2012).
108. Cognetti, F. et al. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). Gynecol. Oncol. 130, 31-37 (2012).
109. Spirig, R. et al. TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. Mol. Immunol. 46, 3178-3182 (2009).
110. Fischgre, J. et al. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells. Int. J. Cancer 127, 696-706 (2010).
111. Chang, I. et al. Endothelin-2 deficiency causes growth retardation, hypothermia, and emphysema in mice. J. Clin. Invest. 123, 2643-2653 (2013).
112. Grimshaw, M. J., Naylor, S. & Balkwill, F. R. Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol. Cancer. Ther. 1, 1273-1281 (2002).
113. Grimshaw, M. J. et al. A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res. 64, 2461-2468 (2004).
114. Hagemann, T. et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF- dependent up-regulation of matrix metalloproteases. Carcinogenesis 25, 1543-1549 (2004).
115. Tanese, K., Fukuma, M., Ishiko, A. & Sakamoto, M. Endothelin-2 is upregulated in basal cell carcinoma under control of Hedgehog signaling pathway. Biochem. Biophys. Res. Commun. 391, 486-491 (2010).
116. Chang, C. Y. et al. NFIB is a governor of epithelial-melanocyte stem cell behaviour in a shared niche. Nature. 495, 98-102 (2013).
117. Hosoda, K. et al. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79, 1267-1276 (1994).
118. Tang, L. et al. Endothelin-3 is produced by metastatic melanoma cells and promotes melanoma cell survival. J. Cutan. Med. Surg. 12, 64-70 (2008).
119. Palladini, A. et al. Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine role. Eur. J. Cancer. 42, 680-687 (2006).
120. Welch, A., Jacobs, M., Wingo, C. & Cain, B. Early progress in epigenetic regulation of endothelin pathway genes. Br. J. Pharmacol. 168, 327-334 (2013).
121. Wang, R. et al. Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer. Int. J. Cancer 132, 1004-1012 (2013).
122. Eltze, E. et al. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. Eur. Urol. 56, 837-845 (2009).
123. Egidy, G. et al. The endothelin system in human glioblastoma. Lab. Invest. 80, 1681-1689 (2000).
124. Anguelova, E. et al. Functional endothelin ET B receptors are selectively expressed in human oligodendrogliomas. Brain Res. Mol. Brain Res. 137, 77-88 (2005).
125. Wfing, P. et al. Endothelin-1, Endothelin-A and Endothelin-B-receptor expression is correlated with VEGF expression and angiogenesis in breast cancer. Clin. Cancer Res. 10, 2393-2400 (2004).
126. Hoosein, M. M. et al. Altered endothelin receptor subtypes in colorectal cancer. Eur. J. Gastroenterol. Hepatol. 19, 775-782 (2007).
127. Liakou, P. et al. Expression patterns of endothelin-1 and its receptors in colorectal cancer. J. Surg. Oncol. 105, 643-649 (2012).
128. Hsu, L. S. et al. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan. Oncol. Rep. 15, 507-511 (2006).
129. Fukui, R. et al. Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line. Gastr. Cancer 10, 123-128 (2007).
130. Tao, K. et al. Quantitative analysis of promoter methylation of the EDNRB gene in gastric cancer. Med. Oncol. 29, 107-112 (2012).
131. Wen, Y. F. et al. Polymorphisms in the endothelin-1 and endothelin A receptor genes and survival in patients with locoregionally advanced nasopharyngeal carcinoma. Clin. Cancer Res. 17, 2451-2458 (2011).
132. Boldrini, L. et al. Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur. J. Cancer. 41, 2828-2835 (2005).
133. Blouquit-Laye, S. et al. Expression of endothelin receptor subtypes in bronchial tumors. Oncol. Rep. 23, 457-463 (2010).
134. Demunter, A., De Wolf-Peeters, C., Degreef, H., Stas, M. & van den Oord, J. J. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch. 438, 485-491 (2001).
135. Smith, S. L. et al. Decreased endothelin receptor B expression in large primary uveal melanomas is associated with early clinical metastasis and short survival. Br. J. Cancer 87, 1308-1313 (2002).
136. Bagnato, A. et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res. 59, 720-727 (1999).
137. Godara, G. et al. Distinct patterns of endothelin axis expression in primary prostate cancer. Urology 70, 209-215 (2007).
138. Nelson, J. B. et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J. Urol. 169, 1143-1149 (2003).
139. Herrmann, E. et al. Expression of the endothelin-axis in the different histologic subtypes of renal cell carcinoma: a tissue microarray analysis. Oncol. Rep. 17, 275-280 (2007).
140. Wuttig, D. et al. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int. J. Cancer 131, e693-e704 (2012).
141. Douglas, M. L., Richardson, M. M. & Nicol, D. L. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma. Cancer 100, 2118-2124 (2004).
142. Yao, M. et al. A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. Int. J. Cancer 123, 1126-1132 (2008).
143. Eltze, E. et al. Expression and prognostic relevance of endothelin-B receptor in vulvar cancer. Oncol. Rep. 18, 305-311 (2007).
144. Nelson, J. B. et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118, 5709-5718 (2012).
145. Chouaid, C., Nathan, F., Pemberton, K. & Morris, T. A Phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 67, 1203-1208 (2011).
146. Nelson, J. B. et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113, 2478-2487 (2008).
147. Carducci, M. A. et al. A Phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110, 1959-1966 (2007).
148. Kefford, R. et al. A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest. New Drugs 25, 247-252 (2007).
149. Kefford, R. F. et al. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol. Cancer 9, 69 (2010).]